UA34947A - Способ моделирования эндогенной интоксикации в эксперименте - Google Patents
Способ моделирования эндогенной интоксикации в эксперименте Download PDFInfo
- Publication number
- UA34947A UA34947A UA99074208A UA99074208A UA34947A UA 34947 A UA34947 A UA 34947A UA 99074208 A UA99074208 A UA 99074208A UA 99074208 A UA99074208 A UA 99074208A UA 34947 A UA34947 A UA 34947A
- Authority
- UA
- Ukraine
- Prior art keywords
- modeling
- endogenous intoxication
- experiment
- toxic substances
- intoxication
- Prior art date
Links
- 230000035987 intoxication Effects 0.000 title claims abstract description 18
- 231100000566 intoxication Toxicity 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000002474 experimental method Methods 0.000 title claims abstract description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims abstract description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 231100000614 poison Toxicity 0.000 claims abstract description 6
- 239000003440 toxic substance Substances 0.000 claims abstract description 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019270 ammonium chloride Nutrition 0.000 claims abstract description 5
- 239000004202 carbamide Substances 0.000 claims abstract description 5
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 5
- 239000004310 lactic acid Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims abstract description 5
- 229940116269 uric acid Drugs 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 4
- 231100000027 toxicology Toxicity 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 229950005499 carbon tetrachloride Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000001819 pancreatic juice Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010050789 Hypochromasia Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Изобретение относится к экспериментальной медицине, а именно к токсикологии. Способ моделирования эндогенной интоксикации в эксперименте включает введение в организм водного раствора смеси токсичных веществ, в качестве токсичных веществ используется хлорид аммония, мочевина, мочевая кислота, молочная кислота.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA99074208A UA34947A (ru) | 1999-07-20 | 1999-07-20 | Способ моделирования эндогенной интоксикации в эксперименте |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA99074208A UA34947A (ru) | 1999-07-20 | 1999-07-20 | Способ моделирования эндогенной интоксикации в эксперименте |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA34947A true UA34947A (ru) | 2001-03-15 |
Family
ID=74204499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99074208A UA34947A (ru) | 1999-07-20 | 1999-07-20 | Способ моделирования эндогенной интоксикации в эксперименте |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA34947A (ru) |
-
1999
- 1999-07-20 UA UA99074208A patent/UA34947A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960005705B1 (ko) | 플로르페니콜의 약제학적 조성물 | |
| CN1263464A (zh) | 含有水溶性酮基布洛芬盐的药用制剂及其应用 | |
| RU94036778A (ru) | Фармацевтические композиции, способы лечения, способ диагностики, способы идентификации, рецепторы, клетки, нуклеиновые кислоты, соединения, антитела, агент связывания рецептора, способ модуляции экспрессии рецептора, способ уничтожения клетки | |
| KR970702033A (ko) | 택산 계열 유도체-기본 약학 조성물(taxane class derivative based pharmaceutical compositions) | |
| ATE426402T1 (de) | Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l | |
| RU2381797C1 (ru) | Способ профилактики системного амилоидоза и его нефропатической формы у экспериментальных животных | |
| HARTMAN | Tissue changes following the use of plasma substitutes | |
| UA34947A (ru) | Способ моделирования эндогенной интоксикации в эксперименте | |
| JPS60120995A (ja) | 新規アミノ酸誘導体の製法 | |
| RU2021812C1 (ru) | Средство для лечения артрологических заболеваний | |
| Krebs et al. | Solubility of Sulphonamides in Relation to Hydrogen-ion Concentration | |
| SU1501129A1 (ru) | Способ моделировани эндогенной интоксикации | |
| EA001099B1 (ru) | Инъекционное лекарственое средство "цитофлавин", обладающее цитопротекторным действием | |
| JPH0586931B2 (ru) | ||
| RU2112504C1 (ru) | Средство для лечения заболеваний предстательной железы "витапрост" | |
| RU2386415C1 (ru) | Способ профилактики системного амилоидоза и его нефропатической формы у экспериментальных животных | |
| Case et al. | Reproductive, acute and subacute toxicity studies with nefopam in laboratory animals | |
| Chenoweth | The toxicity of sodium alginate in cats | |
| Ross | Blockade of the diuretic action of benzothiadiazines | |
| Lustig et al. | Liver damage in acute self-induced hypermanganemia | |
| Gooneratne et al. | Profiles of 67Cu in blood, bile, urine and faeces from 67Cu-primed lambs: effect of 99Mo-labelled tetrathiomolybdate on the metabolism of 67Cu after long-term storage | |
| RU2270672C1 (ru) | Способ профилактики и лечения системного амилоидоза и его нефропатической формы у экспериментальных животных | |
| JPS63132843A (ja) | 抗炎症剤 | |
| JPH01268645A (ja) | シュワルツマン反応抑制剤 | |
| RU2205638C1 (ru) | Антигистаминное средство "бравегил" |